panitumumab sold brand name vectibix fully human monoclonal antibody specific epidermal growth factor receptor also known egf receptor egfr panitumumab manufactured amgen originally developed abgenix inc amgen illumina entered agreement develop companion diagnostic accompany panitumumab approved us food drug administration fda first time september treatment egfrexpressing metastatic colorectal cancer disease progression despite prior panitumumab approved european medicines agency emea health canada treatment refractory egfrexpressing metastatic colorectal cancer patients nonmutated wildtype kras panitumumab first monoclonal antibody demonstrate use kras predictive biomarker panitumumab work patients kras nras panitumumab associated skin rash fatigue nausea diarrhea fever decreased magnesium levels often skin rash noted sun exposed parts body face chest oral antibiotics may needed worsening skin rash one accompanied blisters ulcers otherwise topical steroid creams like hydrocortisone may ocular toxicity keratitis observed patients panitumumab usually necessitating discontinuance clinical trials patients dermatological toxicities severe panitumumab boxed warning cautioning patients skin toxicities typically apparent two weeks beginning treatment severe skin toxicities associated improved progression free survival overall pulmonary fibrosis interstitial lung disease observed clinical egfr transmembrane protein panitumumab works binding extracellular domain egfr preventing activation results halting cascade intracellular signals dependent pharmacokinetics pk panitumumab shows socalled targetmediated disposition however pharmacokinetics approximately linear clinical doses terminal halflife typical male patient kg years age colorectal cancer daysmedical citation needed panitumumab generated using abgenixs xenomouse platform technology engineered mice utilized produce human antibodies abgenix partnered immunex corporation develop antibody amgen acquired immunex amgen acquired abgenix well amgen formed agreement zhejiang beta pharma form amgen beta pharmaceuticals market panitumumab china amgen takeda agreement takeda develop commercialise panitumumab panitumumab licensed dr reddys laboratories india glaxosmithkline ukcitation needed panitumumab initially approved september egfrexpressing metastatic crc disease progression following fluoropyrimidine oxaliplatin irinotecancontaining regimens based results study showed clinical benefit metastatic colorectal cancer july fda updated labels two antiegfr monoclonal antibody drugs panitumumab cetuximab indicated treatment metastatic colorectal cancer include information kras result study demonstrated lack benefit panitumumab patients carried nras also approved firstline agent combination panitumumab studied numerous phase ii iii clinical trials phase iii clinical trials include treatment esophageal urothelial metastatic head neck liver metastasis colorectal early trials showed limited efficacy patients malignant melanoma bladder cancer prostate cancer renal cell although target egfr panitumumab cetuximab differ isotype might differ mechanism action monoclonal antibodies isotype may activate complement pathway mediate antibodydependent cellular cytotoxicity clear time one drug superior one studies drugs noted similar httpsenwikipediaorgwikipanitumumab